A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment. A recent clinical trial found that a ...
Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients. DB-1305/BNT325, a TROP2-targeted antibody ...
A national cohort study found that the incidence of triple-negative breast cancer (TNBC) is highest among Black women living in the most socioeconomically disadvantaged neighborhoods, and the ...
SAGA Diagnostics®, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, joined ...
Researchers from Nankai University and collaborating institutions have identified a novel proteolysis targeting chimera (PROTAC) molecule that effectively and selectively degrades multiple ...
SAN ANTONIO -- More than 70% of patients with advanced triple-negative breast cancer (TNBC) responded to an investigational bispecific antibody targeting PD-L1 and VEGF-A plus chemotherapy, a ...
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ...
Trodelvy showed fewer severe side effects and required fewer dose reductions or discontinuations compared to chemotherapy in TNBC patients. Common side effects, such as neutropenia and diarrhea, were ...
Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC patients. The study's primary endpoint, progression-free survival, favored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results